October 8-10 2014
Renaissance Seattle Hotel, Seattle, WA
This conference will focus on healthcare innovations and point-of-care technologies, and their clinical translation to address challenges in global quality healthcare.
Submission Deadline for Four-Page Papers Extended until Monday 21 July 2014
For more info:
Purpose: The Johns Hopkins Center for Point-of-Care Tests for STDs (JHU C POCT STD) is seeking to facilitate the development of novel detection technologies for Point of Care Tests. Successful applications will describe the development of tests which minimally:
- can detect less than 5,000 elementary bodies of chlamydia/ml
- are rapid (time from sample to result under 4 hours)
- have low-labor burden for sample preparation and assay, and
- will be low cost (under $30/test)
Multiplex assays which can detect chlamydia as well as other sexually transmitted diseases are encouraged.
Full Fast Track Proposals are due August 6, 2014; October 29, 2014; January 7, 2015; by 4pm EST/ET. PDF files may be sent by email to POCT-STD@jhuapl.edu. Only electronic submissions are accepted.
For more info follow the link below.
Moving cancer treatments out of specialized centers and into local clinics or home care settings could significantly increase access to care for patients around the world, while lowering healthcare costs.
To begin a dialogue about the future of these point of care (POC) technologies in cancer care, The Center for Future Technologies in Cancer Care, is hosting aGHDonline Expert Panel from Monday, May 5th to Friday, May 9th.
I hope you’ll join us, as well as our expert panelists from PATH, Dana-Farber Cancer Institute and Harvard Medical School in discussing the current needs and future opportunities for point of care technologies in cancer care.
We look forward to learning more about cancer care in your communities—pleasejoin us on GHDonline today.
Our website now has a resources page! Visit the page for more information regarding cancer care through resources, information, and other websites.
When: Wednesday May 14th at 3:00 PM GMT (10:00 AM ET)
Where: Online at http://www.economicsofcancer.
Dr Otis Brawley, Chief Medical and Scientific Officer of the American Cancer Society will speak on a number of topics related to cancer research including the economics burden of cancer in the US, disparities in health and some point on the future of cancer research.
This Webinar can be viewed at http://www.economicsofcancer.
Point of Care Technology Workshop
June 9-10th, 2014
Our center is hosting the BU-CIMIT Point-of-Care workshop. The day will provide attendees with a working knowledge and practical skill set to assess and apply metrics of success of point- of-care systems in the spaces of diagnosis, device, and drug delivery systems.
- Day 1 will start with talks and discussions on the statistical measures of efficacy and how to value point-of-care interventions; clinical needs assessment; and barriers to delivery in the US and globally.
- Day 2 is a series of case studies and working groups, covering applications in STIs, cancer, and primary care.
Stay tuned for more information about lecturers and other announcements!
|Project 1||Personal Health Network Technology – Chemotherapy||Jill Joseph, University of California, Davis|
|Project 2||A Nanopore-Nanofiber Mesh Biosensor||Mark Grinstaff, Boston University, College of Engineering|
|Project 3||POC Tumor Marker Detection – Ovarian Tumors||Justin Baca, University of New Mexico|
|Project 4||A New Wearable Technology – Chemotherapy Monitoring||Darren Roblyer, Boston University, College of Engineering|
|Project 5||Smartphone App for Chronic Pain Care – Cancer Patient||Robert Jamison, Brigham and Women’s Hospital|
|Project 6||Topical Treatment of Oral Cancer||Manijeh Goldberg, Privo Technologies, Inc.|
|Project 7||Evaluation of mHealth Counseling for Lifestyle Behaviors Among Breast Cancer Survivors||Lisa Quintiliani, Boston University, School of Medicine|
Project Summaries will be posted below soon.
Project #1: Personal Health Network Technology – Chemotherapy
PI: Jill Joseph, University of California, Davis
Project #2: A Nanopore-Nanofiber Mesh Biosensor
PI: Mark Grinstaff, Boston University, COE
Project #3: POC Tumor Marker Detection – Ovarian Tumors
PI: Justin Baca, University of New Mexico
Cancer patients in rural environments and of lower socioeconomic status face several barriers to accessing high quality, regionalized cancer care. Technologies that move tumor marker testing closer to the patient or to the oncologist’s office have the potential to improve access to care and quality of life for patients that must travel long distances for initial evaluations, surveillance visits, or routine cancer treatment. We are developing a point-of-care biosensor for detecting tumor markers for such patients. We will enable a Shear Horizontal Surface Acoustic Wave (SH-SAW) point-of-care sensor system for multiplexed tumor marker detection. While our system would be generalizable to detect any tumor marker with a specific monoclonal antibody, we propose to study tumor markers in ovarian germ cell and epithelial tumors as a model system.
Project #4: A New Wearable Technology – Chemotherapy Monitoring
PI: Darren Roblyer, Boston University, COE
Current chemotherapies and targeted agents for the treatment of solid tumors only extend life or provide cures in a fortunate subset of patients. Treatment success depends on a multitude of biological factors and any combination of non-ideal conditions will contribute to poor response rates and limited treatment efficacy, potentially leading to lengthy regimens that burden the health care system while providing little or no benefit to the patient. There are currently few clinically viable, cost-effective, non-invasive, and non-harmful methods of chemotherapy monitoring and there are no clinically accepted point-of-care (POC) chemotherapy monitoring methods.
Optical techniques such as Diffuse Optical Spectroscopy (DOS) are ideally suited for POC chemotherapy monitoring due to their favorable safety profiles and relative cost-effectiveness. Unfortunately, current DOS instruments have a large footprint (typically the size of a refrigerator) and often incorporate expensive benchtop electrical test equipment leading to total device costs between $50k and $70k. Here we propose two key technology developments necessary to transform DOS into a POC technique. The first is the development of an all-digital DOS measurement platform that will replace prior analog DOS systems. This will greatly reduce instrument footprint (to the size of a briefcase) and simplify overall system design. The second is the development of a new flexible and reusable DOS imaging pad that will collect DOS data from a large tissue field-of-view (FOV) without manual probe scanning. The pad will greatly improve measurement acquisition speed (estimated several seconds to measure a breast tumor compared with up to 1 hour for prior scanning technique), and importantly, will allow for continuous and real-time monitoring of patients during their chemotherapy infusions. Together, these two technology developments will lead to a new generation of portable and wearable digital Diffuse Optical Spectroscopy (dDOS) technology that is suited for POC measurements.
Project #5: Smartphone App for Chronic Pain Care – Cancer Patient
PI: Robert Jamison, Brigham and Women’s Hospital
This study is designed for cancer patients with chronic pain. Many of these patients are virtually homebound with limited support and mobility and may have pain from their disease or from past treatments. The overall aim of the study is to determine the effect of introducing a smartphone pain application (app) to chronic cancer-related pain patents who can assess, monitor, and communicate their status to their providers. To be useful, the components of this program need to be accurate, reliable, inexpensive, easy to use, timely, and acceptable to patients and clinicians. The goal is to introduce technology that will allow patients and physicians to more easily 1) identify factors exacerbating or relieving pain, 2) modify treatment, and 3) help patients to better understand and control their symptoms and symptom management. This study will serve to rigorously assess the outcome of a smartphone pain app. The hope is to gather information to refine the pain app for future use among persons with cancer-related chronic pain.
We will conduct a controlled trial by introducing a smartphone pain app to 20 chronic cancer-related pain patients randomly assigned to the Experimental group and compare outcome over 3 months with 20 patients who will receive treatment as usual (Control). The Smartphone Pain App is designed to monitor pain intensity, activity interference, mood, medication use, side effects and coping, as well as incorporate a body map for identifying the primary areas of pain. The program will also be interactive by offering education and suggestions as prompts in response to elevated ratings of pain, depression, sleep disturbances, etc. along the model of cognitive-behavioral therapy for pain. The program will summarize the patient’s progress and transmit this information to the providers via a link to a server at the Brigham and Women’s Hospital (BWH) Pain Management Center. We hope to learn about the best ways to use information technology in improving the quality of life among persons with cancer-related chronic pain.
Project #6: Topical Treatment of Oral Cancer
PI: Manijeh Goldberg, Privo Technologies, Inc.
Oral cancer (OC) is a complex, disabling, and potentially deadly subgroup of oncology. While its death rate is three times more than cervical cancer – it kills one person per hour per day in the US – it receives minor attention compared to other cancers such as skin or lung cancer. OC is considered an orphan disease (less than 200,000 patients) in the US. More than 50% of oral cancer patients die within the first 5 years of diagnosis due to cancer relapse and tumor recurrence. Chemo resistant recurrence is a major issue for oral cancer patients. This project suggests that local chemotherapy of oral cancer can improve patient outcome and can considerably reduce the systemic toxicity and it focuses on:
1) Can a local and topical chemotherapy reduce the chance of acquired chemo resistance compared to the current standard of care (Intravenous Chemotherapy)
2) Can resistant cancer tumors be destroyed with a high concentration of local chemotherapy without severe sideeffects
Project #7 Evaluation of mHealth Counseling for Lifestyle Behaviors Among Breast Cancer Survivors
PI: Lisa Quintiliani, Boston University, School of Medicine
Tremendous advances in detection and treatment of breast cancer have led to an increasingly large cohort of survivors focused on health promotion and reducing the risk of recurrence. While adjuvant therapy, such as hormone therapy, is often used to prevent cancer recurrence, modification of lifestyle behaviors is also an effective tool to increase quality of life, prevent future cancer recurrence and increase long-term health. However, translating these recommendations into population-wide, inexpensive, sustainable programs for cancer survivors has to date proven largely unrealized. These programs are particularly needed in health disparity-facing populations (i.e., low socio-economic status and/or racial/ethnic minority groups) due to the high burden of cancer incidence and mortality they face. Limited translation is due to many factors including the complexity of lifestyle habits, high patient burden of many behavioral interventions, low levels of engagement and adherence to interventions, and the lack of integration of behavior change tools into daily lifestyles. In this context, there is great promise of mHealth tools that are mobile, simple, and embedded into daily life routines. The long-term goal of this research program is to develop, evaluate and implement effective mHealth technology interventions that improve cancer management outcomes by changing lifestyle behaviors among urban health-disparity facing populations. The objective of the proposed study is to determine the feasibility and preliminary efficacy of an intervention, the mHealth counseling platform for cancer survivors, in which breast cancer survivors receive counseling about lifestyle behaviors (weight, nutrition, and physical activity) from patient navigators trained in evidenced-based behavioral counseling methods. The mHealth platform for cancer survivors has two primary components: 1) a smartphone app that captures patients’ behavioral data using intuitive self-tracking for diet intake and Bluetooth wireless sensors for weight and physical activity and 2) a web-based counseling portal through which navigators view and respond to patients’ behavioral data and assist them in setting goals for changing behaviors consistent with their cancer care plan. We will refine our existing platform (called Dash Mobile) to make it suitable for breast cancer survivors, perform usability testing on the new system, and then conduct a pilot trial in which 20 breast cancer survivors from Boston Medical Center (BMC) receive mHealth counseling. Completing this research will result in preliminary feasibility and efficacy data for a mHealth counseling approach for cancer-related behaviors among breast cancer survivors; forming the basis of a larger randomized efficacy trial and potential commercial vehicles to leverage this new platform.